Group 1 - The stock of Brainstorm Cell Therapeutics (06681) reached a new high of 13.8 HKD since its listing, but later saw a decline of over 14%, with an overall trading range of 32% throughout the day [1] - The stock had previously increased for four consecutive trading days, resulting in a cumulative rise of 125% [1] - As of the report, the stock was down 14.84%, trading at 10.04 HKD, with a total transaction volume of 1.724 billion HKD [1] Group 2 - Starting from September 8, Brainstorm Cell Therapeutics was officially included in the Hong Kong Stock Connect list, attracting southbound capital for stock accumulation [1] - By September 12, northbound investors held 2.1124 million shares, accounting for 1.66% of the total shares [1] - The company is the first in China to develop a medical-grade digital therapy product targeting cognitive impairment, with its core product being the first in the country to receive regulatory approval (registered in September 2018) [1] Group 3 - In the first half of this year, the company reported revenue of 100 million HKD, representing a year-on-year increase of 92.82% [1] - The adjusted net loss for the same period was 88.022 million HKD, which is an increase of 11.64% year-on-year [1]

Core Insights - On September 16, 2025, Alibaba-W (09988), Brainstorm Aurora-B (06681), and Baize Medical (02609) were the top three stocks by trading volume in the Southbound Stock Connect, with trading amounts of 57.96 billion, 55.71 billion, and 48.83 billion respectively [1] - In the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988), Xiaomi Group-W (01810), and PharmaJet-B (02617) led the trading volume, with amounts of 31.74 billion, 18.85 billion, and 18.82 billion respectively [1] Southbound Stock Connect - Top Active Companies - Alibaba-W (09988) had a trading amount of 57.96 billion with a net buying amount of +18.98 billion [2] - Brainstorm Aurora-B (06681) recorded a trading amount of 55.71 billion with a net buying amount of +98.28 million [2] - Baize Medical (02609) achieved a trading amount of 48.83 billion with a net buying amount of +2.17 billion [2] - Meituan-W (03690) had a trading amount of 32.61 billion with a net buying amount of +2.65 billion [2] - The Yingfu Fund (02800) had a trading amount of 31.85 billion with a net selling amount of -31.70 billion [2] Shenzhen-Hong Kong Stock Connect - Top Active Companies - Alibaba-W (09988) had a trading amount of 31.74 billion with a net buying amount of +11.33 billion [2] - Xiaomi Group-W (01810) recorded a trading amount of 18.85 billion with a net selling amount of -3.48 billion [2] - PharmaJet-B (02617) achieved a trading amount of 18.82 billion with a net selling amount of -4.50 billion [2] - Brainstorm Aurora-B (06681) had a trading amount of 18.22 billion with a net buying amount of +26.73 million [2] - Meituan-W (03690) had a trading amount of 18.15 billion with a net buying amount of +4.51 billion [2]

Core Viewpoint - The Hong Kong stock market experienced significant net selling from northbound capital, totaling HKD 31.89 billion on September 16, with the majority coming from the Shanghai-Hong Kong Stock Connect [1] Group 1: Northbound Capital Flow - Northbound capital had a net selling of HKD 29.76 billion through the Shanghai Stock Connect and HKD 2.13 billion through the Shenzhen Stock Connect [1] - The stocks with the highest net buying included Alibaba-W (09988), Meituan-W (03690), and Baize Medical (02609) [1] - The stocks with the highest net selling included the Tracker Fund of Hong Kong (02800), Xiaomi Group-W (01810), and SMIC (00981) [1] Group 2: Individual Stock Performance - Alibaba-W (09988) saw a net inflow of HKD 30.31 billion, supported by recent announcements related to its mapping service and AI developments [4] - Meituan-W (03690) recorded a net inflow of HKD 7.15 billion, bolstered by the successful launch of its international delivery brand Keeta in Kuwait [5] - Baize Medical (02609) and Tongyuan Kang Medical-B (02410) received net inflows of HKD 3.27 billion and HKD 2.96 billion, respectively, following regulatory changes that enhance the clinical trial approval process for innovative drugs [5] Group 3: Notable Net Selling - The Tracker Fund of Hong Kong (02800) faced a significant net outflow of HKD 46.38 billion, with analysts suggesting that while short-term interest rates may benefit the Hong Kong market, the overall outlook remains cautious due to weakening fundamentals [7] - Xiaomi Group-W (01810), SMIC (00981), and Tencent (00700) experienced net outflows of HKD 5.69 billion, HKD 4.12 billion, and HKD 3.86 billion, respectively [8]

Core Viewpoint - On September 15, the Hang Seng Index rose by 0.22%, closing at 26,446.56 points, with a net inflow of 14.473 billion HKD through the southbound trading channel [1] Group 1: Market Activity - The total trading amount for the southbound trading on September 15 was 156.251 billion HKD, with a net buying amount of 14.473 billion HKD [1] - The Shanghai Stock Exchange's southbound trading accounted for 95.161 billion HKD, with a net buying of 6.968 billion HKD, while the Shenzhen Stock Exchange's southbound trading amounted to 61.089 billion HKD, with a net buying of 7.505 billion HKD [1] Group 2: Active Stocks - Alibaba-W was the most actively traded stock on the Shanghai Stock Exchange southbound trading, with a trading amount of 7.960 billion HKD and a net buying of 2.890 billion HKD, closing with a price increase of 2.32% [2] - In the Shenzhen Stock Exchange southbound trading, Alibaba-W also led with a trading amount of 5.047 billion HKD and a net buying of 2.395 billion HKD, maintaining the same closing price increase of 2.32% [2] - The stock with the highest net selling was Xiaomi Group-W, with a net selling amount of 724 million HKD, while its closing price increased by 1.90% [1][2]

Core Insights - On September 15, 2025, Alibaba-W (09988), Pop Mart (09992), and Yaojie Ankang-B (02617) were the top three stocks by trading volume in the Southbound Stock Connect, with trading amounts of 79.60 billion, 29.45 billion, and 26.94 billion respectively [1] - In the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988), Xiaomi Group-W (01810), and Tencent Holdings (00700) led the trading volume, with amounts of 50.47 billion, 25.76 billion, and 18.75 billion respectively [1] Southbound Stock Connect - Top Active Companies - Alibaba-W (09988) had a trading amount of 79.60 billion with a net buying amount of +28.90 billion [2] - Pop Mart (09992) recorded a trading amount of 29.45 billion with a net selling amount of -3.25 billion [2] - Yaojie Ankang-B (02617) had a trading amount of 26.94 billion with a net selling amount of -1.39 billion [2] - Other notable companies included Brainstorm Aurora-B (06681) with a trading amount of 26.34 billion and a net buying amount of +2.66 billion [2] - Tencent Holdings (00700) had a trading amount of 23.45 billion with a net selling amount of -2.21 billion [2] Shenzhen-Hong Kong Stock Connect - Top Active Companies - Alibaba-W (09988) led with a trading amount of 50.47 billion and a net buying amount of +23.95 billion [2] - Xiaomi Group-W (01810) had a trading amount of 25.76 billion with a net buying amount of +457.14 million [2] - Tencent Holdings (00700) recorded a trading amount of 18.75 billion with a net buying amount of +26.27 million [2] - Pop Mart (09992) had a trading amount of 18.72 billion with a net selling amount of -1.27 billion [2] - Other significant companies included Meituan-W (03690) with a trading amount of 15.29 billion and a net buying amount of +3.88 billion [2]

Core Viewpoint - The stock of Brainstorm Cell Therapeutics (06681) experienced a dramatic surge, rising over 83% to reach a new high of 13.78 HKD, driven by its inclusion in the Hong Kong Stock Connect and the scarcity of its position as the first domestic company focused on digital therapies for cognitive disorders [1][2]. Group 1: Stock Performance Metrics - From September 8 to September 15, the stock exhibited an impressive increase of 88.91%, with a volatility of 158.23% and a turnover rate of 30.107%, resulting in a total trading volume of 35.4 billion HKD [2][3]. - The highest price reached was 13.78 HKD, while the lowest was 5.22 HKD, with a total volume of 3.812 billion shares traded during this period [3]. Group 2: Market Dynamics - The significant turnover rate of 30.107% indicates a major shift in the shareholder structure, with nearly one-third of the floating shares changing hands, suggesting a complete overhaul of the previous holding patterns [3]. - The average holding cost for the market has risen to 9.286 HKD, establishing a solid support level for future price movements [3]. Group 3: Trading Behavior Analysis - The K-line patterns revealed a complex interplay between bulls and bears, with four days of price increases but only three days showing positive closing prices, indicating a fierce battle between buying and selling pressures [4][6]. - Despite the apparent selling pressure, the volume of buying (3.572 billion shares) was significantly higher than selling (0.24 billion shares), demonstrating strong underlying demand [7]. Group 4: Investor Composition - Data shows that southbound funds were the primary drivers of this rally, with nearly 944.3 million shares acquired through the Hong Kong Stock Connect within just five days, representing 0.7458% of the total issued shares [8][10]. - In contrast, local brokers like Yao Cai Securities and Bank of China (Hong Kong) showed much smaller increases in holdings, indicating that their activities were more of a follow-up to the main buying momentum [10]. Group 5: Future Outlook - As of September 15, the stock was trading at 10.22 HKD, reflecting a 36.27% increase for the day, with a trading volume of 21.43 billion HKD, suggesting a transition into a new phase of market activity [11]. - The market is currently in a high-level consolidation phase after a rapid price increase, with future price stability dependent on continued inflows from southbound funds and the company's ability to validate its growth potential [11].

Core Viewpoint - The stock of Brainstorm Cell Therapeutics (06681) experienced a dramatic surge, rising over 83% to reach a new high of 13.78 HKD, driven by its inclusion in the Hong Kong Stock Connect and the scarcity of its position as the first domestic company focused on digital therapies for cognitive disorders [1][2]. Group 1: Stock Performance and Market Dynamics - From September 8 to September 15, the stock exhibited an impressive increase of 88.91%, with a volatility of 158.23% and a turnover rate of 30.107%, resulting in a total trading volume of 35.4 billion HKD [1][2]. - The turnover rate of 30.107% indicates a significant shift in shareholding structure, with nearly one-third of the floating shares changing hands, suggesting a complete overhaul of the previous holding patterns [2]. - The average holding cost for the market has risen to 9.286 HKD, establishing a solid support line for future price movements [2]. Group 2: Market Sentiment and Trading Behavior - The K-line pattern during this period showed a paradox where the stock rose for four days but only recorded three bullish candles, indicating a fierce battle between bulls and bears [3][5]. - Despite the apparent selling pressure, the volume of buying was significantly higher, with bullish volume at 3.572 billion shares, which is 14.88 times the bearish volume, indicating strong buying interest [6]. Group 3: Investor Composition and Market Drivers - Southbound funds were identified as the primary drivers of this rally, with nearly 944.3 million shares acquired through the Stock Connect channels within just five days, representing 0.7458% of the total issued shares [7][9]. - In contrast, local brokers like Yao Cai Securities and Bank of China (Hong Kong) showed much smaller increases in holdings, indicating that their activities were more of a follow-up to the main buying momentum [9]. Group 4: Future Outlook - The stock is currently in a high volatility phase following a significant price increase, with ongoing battles between buyers and sellers in the 10.00-11.00 HKD range [10]. - The future price stability will depend on two key factors: the continued inflow of southbound funds and the company's ability to validate its high growth potential to match the new valuation [10].

Group 1 - A total of 161 stocks reached a 52-week high as of September 15, with notable performers including Yaojie Ankang-B (02617) at 71.60%, Chengan Technology (08131) at 60.83%, and Brainstorm Aurora-B (06681) at 45.51% [1] - The highest closing price for Yaojie Ankang-B was 415.000, with a peak of 431.400, indicating strong market interest [1] - Chengan Technology's stock closed at 0.128, reaching a high of 0.193, reflecting significant growth potential [1] Group 2 - Other notable stocks that reached new highs include Baize Medical (02609) with a high rate of 33.61%, and BENG SOON MACH (01987) at 27.66% [1] - The list of stocks achieving new highs also includes Jinsheng Group (00794) at 26.67% and Feiyu Technology (01022) at 21.52% [1] - The data indicates a robust performance across various sectors, suggesting a positive market sentiment [1] Group 3 - The report also highlights stocks that reached new lows, with Minshang Chuangke (01632) experiencing a decline of 34.71% [5] - Other stocks that saw significant drops include XI Ernan Tesla (07366) at -17.65% and XI Ernan Tesla-U (09366) at -17.17% [5] - The presence of declining stocks alongside those reaching new highs indicates a mixed market environment [5]

Group 1 - The Hang Seng Index rose by 0.29%, gaining 75 points to reach 26,463 points, while the Hang Seng Tech Index increased by 1.11%. The early trading volume in Hong Kong was HKD 162 billion [1] - CRO concept stocks saw significant gains, with Kanglong Chemical (03759) rising over 8% due to accelerated clinical trial review and approval processes. Other notable performers included Zhaoyan New Drug (06127) up 7%, WuXi Biologics (02269) up 5.5%, and Kelaiying (06821) up 4.2% [1] Group 2 - Yaojie Ankang (02617) surged over 33% after being included in the Hong Kong Stock Connect list, effective from September 8 [2] - The lithium battery sector performed well, with Morgan Stanley issuing a positive report on CATL, as market attention shifts to lithium demand expectations for next year. Notable stock movements included Zhongxin Hang (03931) up 4%, CATL (03750) up 7%, and Ganfeng Lithium (01772) up 4% [2] Group 3 - Yunfeng Financial (00376) increased by over 19%, with its stock price doubling within the month following the approval of its virtual asset trading services [3] Group 4 - Ruipu Lanjun (00666) rose nearly 2%, driven by sustained high production levels at major battery manufacturers and a significant increase in the company's energy storage battery shipments [4] Group 5 - Hushang Ayi (02589) gained over 8% after being included in the Hong Kong Stock Connect list, with stable growth in store numbers during the first half of the year [5] - Brainstorm Cell Therapeutics-B (06681) saw a dramatic rise, initially up 83% to a record high, and closing up 36%, with a cumulative increase of over 130% since its inclusion in the Stock Connect list on September 8. The company is noted for developing the first medical-grade digital therapy product for cognitive disorders in China [5] Group 6 - Baiao Saitu-B (02315) increased by over 11% after signing an antibody selection rights evaluation agreement with Merck to advance antibody-drug conjugate lipid delivery solutions [6] Group 7 - Domestic property stocks collectively declined, with Shimao Group (00813) falling nearly 5% and Zhongliang Holdings (02772) dropping over 3% [7]

Group 1 - The market perceives that companies listed on the Hong Kong stock market benefit from being included in the Hong Kong Stock Connect, as it attracts southbound capital and enhances company visibility [1] - Brain动极光-B (06681.HK) experienced a significant price increase, rising by 32% last Friday and peaking at over 80% before a notable pullback, ultimately trading at HKD 10.4, reflecting a nearly 40% increase [1] - Since entering the Hong Kong Stock Connect, Brain动极光-B has seen its stock price nearly double, with a peak increase exceeding 100% within a week [1] Group 2 - Brain动极光 is the first Chinese company to combine brain science with advanced artificial intelligence to develop medical-grade digital therapy products for cognitive impairments [3] - The company's product pipeline addresses a wide range of cognitive impairments caused by vascular diseases, neurodegenerative diseases, mental disorders, and developmental defects in children [3] - In the first half of this year, Brain动极光 reported revenue of RMB 100 million, marking a year-on-year growth of 92.82% [3] Group 3 - Other stocks that entered the Hong Kong Stock Connect on September 8 also experienced significant price increases, such as药捷安康-B (02617.HK) with a cumulative rise of over 220% and映恩生物-B (09606.HK) with a cumulative rise of over 30% [3]